TRIMPEX
LOE ApproachingNDAORALTABLET
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIMPEX is an oral small-molecule tablet approved by Roche in 1980 for an undisclosed indication. The specific mechanism of action, pharmacologic class, and therapeutic area remain proprietary or unstated in available data. This legacy product represents a mature franchise in the pharmaceutical portfolio.
LOE Approaching
Approaching loss of exclusivity signals organizational focus on retention strategies, line extensions, or transition planning; commercial teams likely contracted or pivoting to generic defense and patient loyalty programs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIMPEX offers limited external career visibility (zero linked job postings) and positions candidates in legacy product management and LOE defense strategies. Roles center on margin protection, generic transition planning, and organizational restructuring rather than growth or innovation.
Brand ManagerCommercial Operations
Worked on TRIMPEX at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.